TY - JOUR
T1 - Quantitative 18F-FDG PET-CT can assess presence and extent of interstitial lung disease in early severe diffuse cutaneous systemic sclerosis.
AU - Broens, Bo
AU - Nossent, Esther J
AU - Meijboom, Lilian J
AU - Zwezerijnen, Gerben J C
AU - Spierings, Julia
AU - de Vries-Bouwstra, Jeska K
AU - van Laar, Jacob M
AU - van der Laken, Conny J
AU - Voskuyl, Alexandre E
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12/19
Y1 - 2024/12/19
N2 - Background: This study aimed to assess the quantitative uptake of 18F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung disease (ILD), compared to controls. In patients with SSc-ILD, 18F-FDG uptake was correlated to high-resolution computed tomography (HRCT) and pulmonary function test (PFT) parameters. Methods: A prospective, cross-sectional study was conducted, involving 15 patients with SSc-ILD, 5 patients with SSc without ILD, and 7 controls without SSc. 18F-FDG PET-CT scans were performed following standardized protocols, and quantitative analysis of tracer uptake was conducted in predefined lung regions. In addition, HRCT scans were evaluated for ILD-related radiologic abnormalities. Between-group differences were compared with non-parametric tests, while correlations with PFT parameters were analyzed using Spearman correlation coefficients. Results: 18F-FDG uptake was mainly increased in the dorsobasal lung fields of patients with SSc-ILD compared to SSc without ILD and controls (p = 0.03 and p < 0.001, respectively). 18F-FDG uptake was higher in SSc patients with extensive ILD (≥ 20% vs < 20%, p = 0.04) and correlated with lower DLCO% (R = -0.59, p = 0.02). Ground-glass opacities, with or without reticulation, corresponded to increased 18F-FDG uptake. Conclusions: 18F-FDG PET-CT can detect metabolic activity in the lungs of patients with early severe diffuse cutaneous SSc and ILD, correlating with higher ILD extent (≥ 20%) and lower DLCO%. These results suggest the potential utility of 18F-FDG PET-CT in the early detection of ILD (progression) and aiding in risk stratification.
AB - Background: This study aimed to assess the quantitative uptake of 18F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung disease (ILD), compared to controls. In patients with SSc-ILD, 18F-FDG uptake was correlated to high-resolution computed tomography (HRCT) and pulmonary function test (PFT) parameters. Methods: A prospective, cross-sectional study was conducted, involving 15 patients with SSc-ILD, 5 patients with SSc without ILD, and 7 controls without SSc. 18F-FDG PET-CT scans were performed following standardized protocols, and quantitative analysis of tracer uptake was conducted in predefined lung regions. In addition, HRCT scans were evaluated for ILD-related radiologic abnormalities. Between-group differences were compared with non-parametric tests, while correlations with PFT parameters were analyzed using Spearman correlation coefficients. Results: 18F-FDG uptake was mainly increased in the dorsobasal lung fields of patients with SSc-ILD compared to SSc without ILD and controls (p = 0.03 and p < 0.001, respectively). 18F-FDG uptake was higher in SSc patients with extensive ILD (≥ 20% vs < 20%, p = 0.04) and correlated with lower DLCO% (R = -0.59, p = 0.02). Ground-glass opacities, with or without reticulation, corresponded to increased 18F-FDG uptake. Conclusions: 18F-FDG PET-CT can detect metabolic activity in the lungs of patients with early severe diffuse cutaneous SSc and ILD, correlating with higher ILD extent (≥ 20%) and lower DLCO%. These results suggest the potential utility of 18F-FDG PET-CT in the early detection of ILD (progression) and aiding in risk stratification.
KW - Imaging
KW - Interstitial lung disease
KW - Positron Emission Tomography
KW - Systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85212486083&partnerID=8YFLogxK
U2 - 10.1186/s13075-024-03447-x
DO - 10.1186/s13075-024-03447-x
M3 - Article
C2 - 39702262
SN - 1478-6354
VL - 26
JO - Arthritis research & therapy
JF - Arthritis research & therapy
IS - 1
M1 - 219
ER -